LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 151

Suchoptionen

  1. Artikel ; Online: Relationship between anti-fungal effects and lung exposure of PC945, a novel inhaled antifungal agent, in Aspergillus fumigatus infected mice: Pulmonary PK-PD analysis of anti-fungal PC945.

    Ito, Kazuhiro / Kizawa, Yasuo / Kimura, Genki / Nishimoto, Yuki / Daly, Leah / Knowles, Ian / Hows, Mark / Ayrton, John / Strong, Pete

    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

    2021  Band 163, Seite(n) 105878

    Abstract: PC945 is a novel antifungal agent, optimised for inhaled treatment. In this study, the relationship between antifungal effects of PC945 and its exposure in the lungs was investigated in Aspergillus fumigatus intranasally infected, temporarily neutropenic ...

    Abstract PC945 is a novel antifungal agent, optimised for inhaled treatment. In this study, the relationship between antifungal effects of PC945 and its exposure in the lungs was investigated in Aspergillus fumigatus intranasally infected, temporarily neutropenic mice. Mice were given prophylactic PC945 intranasally once daily (0.56 µg/mouse) on either Day -7 to 0 (8 doses) or Day -1 to 0 (2 doses). Lung tissue, plasma and bronchoalveolar lavage (BAL) fluid were collected 24 or 72 h post A. fumigatus inoculation for biomarker and pharmacokinetic analyses. BAL cell pellets and supernatants were prepared separately by centrifugation. 8 prophylactic doses of PC945 were found to demonstrate significantly stronger antifungal effects (lung fungal burden and galactomannan (GM) in BAL and plasma) than prophylaxis with 2 doses. PC945 concentrations were below the limit of detection in plasma but readily measured in lung extracts. The concentrations were much higher after extended prophylaxis (709 and 312 ng/g of lung) than short prophylaxis (301 and 195 ng/g of lung) at 24 and 72 h post last dose, respectively, suggesting PC945 accumulation in whole lung after repeat dosing although it was likely to be a mixture of dissolved and undissolved PC945, meaning that the data should be interpreted with caution. Interestingly, low concentrations of PC945 were detected in BAL supernatant (6.6 and 1.9 ng/ml) whereas high levels of PC945 were measured in BAL cell pellets (626 and 406 ng/ml) at 24 and 72 h post last dose, respectively, in extended prophylaxis. In addition, the PC945 concentrations in BAL cells showed a statistically significant correlation with measured anti-fungal activities. These observations will be pursued, and it is intended that BAL cell concentrations of PC945 be measured in future clinical studies rather than standard measurement in BAL itself. Thus, PC945's profile makes it an attractive potential prophylactic agent for the prevention of pulmonary fungal infections.
    Mesh-Begriff(e) Animals ; Antifungal Agents/pharmacology ; Aspergillus fumigatus ; Bronchoalveolar Lavage Fluid ; Disease Models, Animal ; Lung ; Mannans ; Mice
    Chemische Substanzen Antifungal Agents ; Mannans
    Sprache Englisch
    Erscheinungsdatum 2021-05-18
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article
    ZDB-ID 1154366-8
    ISSN 1879-0720 ; 0928-0987
    ISSN (online) 1879-0720
    ISSN 0928-0987
    DOI 10.1016/j.ejps.2021.105878
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel: Status of umbilical cord blood transplantation in the year 2001.

    Hows, J M

    Journal of clinical pathology

    2001  Band 54, Heft 6, Seite(n) 428–434

    Abstract: Umbilical cord blood (UCB) transplantation is limited to small recipients because of the low haemopoietic cell dose. Children from ethnic minority groups may benefit most from cord blood transplantation. Cohort controlled retrospective data indicate that ...

    Abstract Umbilical cord blood (UCB) transplantation is limited to small recipients because of the low haemopoietic cell dose. Children from ethnic minority groups may benefit most from cord blood transplantation. Cohort controlled retrospective data indicate that there is significantly less acute and chronic graft versus host disease associated with the transplantation of human major histocompatibility complex (HLA) identical sibling cord blood compared with HLA identical sibling marrow. Controlled data are not yet available to confirm this observation in unrelated donor cord blood transplantation. The difference in leukaemic relapse seen after cord blood compared with bone marrow transplantation is also unknown. Tentative recommendations for the use of umbilical cord blood for transplantation are as follows. Collection is indicated from healthy newborn siblings when urgent transplantation is required for an older child in a family. The haematologist responsible for the older child, with the approval of the family and the obstetric team, should contact the medical director of the nearest cord blood bank to discuss arrangements for the UCB to be collected and HLA typed. Antenatal blood sampling to HLA type the fetus is not recommended. Umbilical cord blood should be considered when allogeneic transplantation is the treatment of choice for a child who does not have an HLA identical sibling, or a well matched unrelated adult volunteer donor. The potential advantages and disadvantages of using an HLA haplotype matched peripheral blood stem cell family donor rather than an unrelated cord blood donation should be discussed. There are no comparative data available as yet. At present, UCB transplantation should only be considered if a suitably matched donation contains at least 2 x 10(7)/kg nucleated cells. Effectively, this means that most adults and larger children are not suitable recipients.
    Mesh-Begriff(e) Animals ; Blood Banks ; Fetal Blood/cytology ; Graft Survival ; Graft vs Host Disease/prevention & control ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Leukemia/therapy ; Mice
    Sprache Englisch
    Erscheinungsdatum 2001-02-06
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 80261-x
    ISSN 1472-4146 ; 0021-9746
    ISSN (online) 1472-4146
    ISSN 0021-9746
    DOI 10.1136/jcp.54.6.428
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel: Severe aplastic anaemia: the patient without a HLA-identical sibling.

    Hows, J M

    British journal of haematology

    1991  Band 77, Heft 1, Seite(n) 1–4

    Mesh-Begriff(e) Anemia, Aplastic/genetics ; Anemia, Aplastic/surgery ; Anemia, Aplastic/therapy ; Bone Marrow Transplantation ; Family ; HLA Antigens/genetics ; Humans ; Tissue Donors
    Chemische Substanzen HLA Antigens
    Sprache Englisch
    Erscheinungsdatum 1991-01
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/j.1365-2141.1991.tb07940.x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Paediatric bone marrow transplantation using donors other than HLA genotypically identical siblings.

    Hows, J M

    Archives of disease in childhood

    1991  Band 66, Heft 4, Seite(n) 546–550

    Mesh-Begriff(e) Anemia, Aplastic/surgery ; Bone Marrow Transplantation/immunology ; Child ; HLA Antigens/analysis ; Histocompatibility Testing/methods ; Humans ; Leukemia/surgery ; Parents ; Tissue Banks ; Tissue Donors ; Tissue and Organ Procurement
    Chemische Substanzen HLA Antigens
    Sprache Englisch
    Erscheinungsdatum 1991-04
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 524-1
    ISSN 1468-2044 ; 0003-9888 ; 1359-2998
    ISSN (online) 1468-2044
    ISSN 0003-9888 ; 1359-2998
    DOI 10.1136/adc.66.4.546
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: Mechanisms of graft failure after human marrow transplantation: a review.

    Hows, J M

    Immunology letters

    1991  Band 29, Heft 1-2, Seite(n) 77–80

    Abstract: Graft failure (GF) following bone marrow transplantation (BMT) in man is usually attributed to allograft rejection; however, other mechanisms of GF exist. Exposure of the developing allograft to viruses, myelotoxic drugs, and damage to the host-derived ... ...

    Abstract Graft failure (GF) following bone marrow transplantation (BMT) in man is usually attributed to allograft rejection; however, other mechanisms of GF exist. Exposure of the developing allograft to viruses, myelotoxic drugs, and damage to the host-derived marrow stroma during graft-versus-host disease (GVHD) may all cause GF. Later, in the posttransplant course, recurrence of the original disease may ultimately destroy or replace the graft. Overall allogeneic rejection remains the most important cause of GF and most in vivo and in vitro evidence points to a T cell mechanism. The incidence of rejection after clinical BMT is very variable and highly dependent on HLA and non HLA histocompatibility differences between donor and recipient, the level of recipient sensitisation pre-BMT and the immunosuppressive protocols used pre-transplant and for the prevention of GVHD.
    Mesh-Begriff(e) Bone Marrow Transplantation/immunology ; Graft Rejection/drug effects ; Graft Rejection/immunology ; Graft vs Host Disease/immunology ; HLA Antigens/immunology ; Histocompatibility Testing ; Humans ; Immunosuppressive Agents/therapeutic use ; Tissue Donors
    Chemische Substanzen HLA Antigens ; Immunosuppressive Agents
    Sprache Englisch
    Erscheinungsdatum 1991-07
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Review
    ZDB-ID 445150-8
    ISSN 1879-0542 ; 0165-2478
    ISSN (online) 1879-0542
    ISSN 0165-2478
    DOI 10.1016/0165-2478(91)90204-n
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel: Unrelated donor bone marrow transplantation for severe aplastic anaemia and Fanconi's anaemia.

    Hows, J M

    Bone marrow transplantation

    1989  Band 4 Suppl 4, Seite(n) 126–128

    Mesh-Begriff(e) Anemia, Aplastic/surgery ; Bone Marrow Transplantation ; Fanconi Anemia/surgery ; HLA Antigens ; Humans ; Immunosuppression ; Pilot Projects ; Tissue Donors ; Transplantation, Homologous
    Chemische Substanzen HLA Antigens
    Sprache Englisch
    Erscheinungsdatum 1989-12
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 632854-4
    ISSN 1476-5365 ; 0268-3369 ; 0951-3078
    ISSN (online) 1476-5365
    ISSN 0268-3369 ; 0951-3078
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel: Unrelated donor bone marrow transplantation. Current concepts and future prospects.

    Hows, J M

    Beitrage zur Infusionstherapie = Contributions to infusion therapy

    1989  Band 24, Seite(n) 172–179

    Abstract: The use of unrelated donor bone marrow transplantation (UD-BMT) has the potential to extend the availability of BMT to the majority of patients in whom allogeneic BMT is the preferred treatment. Within the next five years it is likely that sufficient ... ...

    Abstract The use of unrelated donor bone marrow transplantation (UD-BMT) has the potential to extend the availability of BMT to the majority of patients in whom allogeneic BMT is the preferred treatment. Within the next five years it is likely that sufficient clinical and laboratory data will be available to decide if wider investment of health resources into this procedure is justified.
    Mesh-Begriff(e) Bone Marrow Transplantation/methods ; Forecasting ; Graft Rejection ; Graft vs Host Disease/prevention & control ; Histocompatibility Testing/methods ; Humans ; Postoperative Complications/prevention & control ; Tissue and Organ Procurement
    Sprache Englisch
    Erscheinungsdatum 1989
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ISSN 1011-6974
    ISSN 1011-6974
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.

    Brookes, Daniel W / Coates, Matthew / Allen, Heather / Daly, Leah / Constant, Samuel / Huang, Song / Hows, Mark / Davis, Amanda / Cass, Lindsey / Ayrton, John / Knowles, Ian / Strong, Pete / Rapeport, Garth / Ito, Kazuhiro

    British journal of pharmacology

    2018  Band 175, Heft 12, Seite(n) 2520–2534

    Abstract: Background and purpose: Effective anti-respiratory syncytial virus (RSV) agents are still not available for clinical use. Current major targets are virus surface proteins, such as a fusion protein involved in viral entry, but agents effective after RSV ... ...

    Abstract Background and purpose: Effective anti-respiratory syncytial virus (RSV) agents are still not available for clinical use. Current major targets are virus surface proteins, such as a fusion protein involved in viral entry, but agents effective after RSV infection is established are required. Here we have investigated the effects of late therapeutic intervention with a novel inhaled RSV polymerase inhibitor, PC786, on RSV infection in human airway epithelium.
    Experimental approach: Air liquid interface-cultured bronchial or small airway epithelium was infected with RSVA2. PC786 was applied apically or basolaterally once daily following peak virus load on Day 3 post inoculation. Apical wash was collected daily for determination of viral burden by PCR and plaque assay (primary endpoints) and biomarker analyses. The effects were compared with those of ALS-8112, an anti-RSV nucleoside analogue, and GS-5806, a fusion-protein inhibitor, which were treated basolaterally.
    Key results: Late intervention with GS-5806 did not show significant anti-viral effects, but PC786 produced potent, concentration-dependent inhibition of viral replication with viral load falling below detectable limits 3 days after treatment commenced in airway epithelium. These effects were superior to those of ALS-8112. PC786 showed inhibitory activities against RSV-induced increases of CCL5, IL-6, double-strand DNA and mucin. The effects of PC786 were also confirmed in small airway epithelium.
    Conclusion and implications: Late therapeutic intervention with the RSV polymerase inhibitor, PC786, reduced the viral burden quickly in human airway epithelium. Thus, PC786 demonstrates the potential to be an effective therapeutic agent to treat active RSV infection.
    Mesh-Begriff(e) Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Benzamides ; Benzazepines ; DNA-Directed RNA Polymerases/antagonists & inhibitors ; DNA-Directed RNA Polymerases/metabolism ; Dose-Response Relationship, Drug ; Epithelium/drug effects ; Epithelium/metabolism ; Epithelium/virology ; HeLa Cells ; Humans ; Microbial Sensitivity Tests ; Respiratory Mucosa/drug effects ; Respiratory Mucosa/metabolism ; Respiratory Mucosa/virology ; Respiratory Syncytial Virus Infections/drug therapy ; Respiratory Syncytial Virus Infections/metabolism ; Respiratory Syncytial Virus, Human/drug effects ; Spiro Compounds/chemistry ; Spiro Compounds/pharmacology ; Structure-Activity Relationship ; Virus Replication/drug effects
    Chemische Substanzen Antiviral Agents ; Benzamides ; Benzazepines ; Spiro Compounds ; DNA-Directed RNA Polymerases (EC 2.7.7.6) ; PC-786 (MC0MD9J0F4)
    Sprache Englisch
    Erscheinungsdatum 2018-05-02
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 80081-8
    ISSN 1476-5381 ; 0007-1188
    ISSN (online) 1476-5381
    ISSN 0007-1188
    DOI 10.1111/bph.14221
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Aplastic anaemia in association with coeliac disease: a series of three cases.

    Grey-Davies, E / Hows, J M / Marsh, J C W

    British journal of haematology

    2008  Band 143, Heft 2, Seite(n) 258–260

    Abstract: We report a series of three patients in whom the diagnoses of aplastic anaemia (AA) and coeliac disease were made concurrently. Haematological manifestations of coeliac disease are well described but this is the first report to suggest an association ... ...

    Abstract We report a series of three patients in whom the diagnoses of aplastic anaemia (AA) and coeliac disease were made concurrently. Haematological manifestations of coeliac disease are well described but this is the first report to suggest an association with aplastic anaemia. 'Silent/atypical coeliac disease', in the absence of gastrointestinal symptoms, is increasingly recognised and patients may present with generalised symptoms, such as malaise and fatigue, which are easily attributable to AA. Immunosuppressive therapy for AA could modulate the course of celiac disease. We recommend clinicians should be vigilant for signs of coeliac disease in patients with AA.
    Mesh-Begriff(e) Adult ; Anemia, Aplastic/blood ; Anemia, Aplastic/complications ; Anemia, Aplastic/surgery ; Bone Marrow Transplantation ; Celiac Disease/blood ; Celiac Disease/complications ; Celiac Disease/surgery ; Combined Modality Therapy ; Cyclosporine/therapeutic use ; Fatigue/etiology ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Middle Aged ; Young Adult
    Chemische Substanzen Immunosuppressive Agents ; Cyclosporine (83HN0GTJ6D)
    Sprache Englisch
    Erscheinungsdatum 2008-10
    Erscheinungsland England
    Dokumenttyp Case Reports ; Journal Article
    ZDB-ID 80077-6
    ISSN 1365-2141 ; 0007-1048
    ISSN (online) 1365-2141
    ISSN 0007-1048
    DOI 10.1111/j.1365-2141.2008.07341.x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel: Histocompatible unrelated donors for bone marrow transplantation.

    Hows, J M

    Bone marrow transplantation

    1987  Band 1, Heft 3, Seite(n) 259–263

    Abstract: Bone marrow transplantation using HLA one haplotype mismatched family donors has been associated with a high incidence of severe graft-versus-host disease, and an increased risk of graft failure. Recently, the use of histocompatible unrelated donors has ... ...

    Abstract Bone marrow transplantation using HLA one haplotype mismatched family donors has been associated with a high incidence of severe graft-versus-host disease, and an increased risk of graft failure. Recently, the use of histocompatible unrelated donors has been investigated when an HLA genotypically identical sibling is not available. Conventional histocompatibility testing of potential unrelated donors does not always predict alloreactivity in vivo. In this review, the preliminary results of histocompatible unrelated transplants are presented and methods of matching unrelated donors discussed.
    Mesh-Begriff(e) Bone Marrow Transplantation ; Family ; HLA Antigens/genetics ; Humans ; Tissue Donors
    Chemische Substanzen HLA Antigens
    Sprache Englisch
    Erscheinungsdatum 1987-02
    Erscheinungsland England
    Dokumenttyp Journal Article ; Review
    ZDB-ID 632854-4
    ISSN 1476-5365 ; 0268-3369 ; 0951-3078
    ISSN (online) 1476-5365
    ISSN 0268-3369 ; 0951-3078
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang